MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.97 Billion EUR | -11.71% |
| 2022 | 2.23 Billion EUR | -3.11% |
| 2021 | 2.31 Billion EUR | 122.64% |
| 2020 | 1.03 Billion EUR | 920.46% |
| 2019 | 101.73 Million EUR | 101.9% |
| 2018 | 50.39 Million EUR | -11.17% |
| 2017 | 56.72 Million EUR | 17.84% |
| 2016 | 48.13 Million EUR | 28.91% |
| 2015 | 37.34 Million EUR | -51.92% |
| 2014 | 77.67 Million EUR | -18.67% |
| 2013 | 95.51 Million EUR | 328.71% |
| 2012 | 22.27 Million EUR | -28.76% |
| 2011 | 31.27 Million EUR | 17.43% |
| 2010 | 26.63 Million EUR | -17.18% |
| 2009 | 32.15 Million EUR | -22.15% |
| 2008 | 41.3 Million EUR | 5.44% |
| 2007 | 39.17 Million EUR | 40.96% |
| 2006 | 27.79 Million EUR | 72.53% |
| 2005 | 16.1 Million EUR | -1.88% |
| 2004 | 16.41 Million EUR | 5.4% |
| 2003 | 15.57 Million EUR | -28.48% |
| 2002 | 21.77 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.09 Billion EUR | 5.86% |
| 2023 FY | 1.97 Billion EUR | -11.71% |
| 2023 Q3 | 2.16 Billion EUR | 2.71% |
| 2023 Q1 | 2.13 Billion EUR | -4.78% |
| 2023 Q4 | 1.97 Billion EUR | -8.8% |
| 2023 Q2 | 2.11 Billion EUR | -1.02% |
| 2022 Q2 | 2.53 Billion EUR | 9.52% |
| 2022 Q1 | 2.31 Billion EUR | 0.18% |
| 2022 Q3 | 2.93 Billion EUR | 15.74% |
| 2022 Q4 | 2.23 Billion EUR | -23.7% |
| 2022 FY | 2.23 Billion EUR | -3.11% |
| 2021 Q4 | 2.31 Billion EUR | 1.08% |
| 2021 FY | 2.31 Billion EUR | 122.64% |
| 2021 Q1 | 1.07 Billion EUR | 3.09% |
| 2021 Q2 | 976 Million EUR | -8.81% |
| 2021 Q3 | 2.28 Billion EUR | 134.29% |
| 2020 Q1 | 666.64 Million EUR | 555.26% |
| 2020 FY | 1.03 Billion EUR | 920.46% |
| 2020 Q4 | 1.03 Billion EUR | 32.74% |
| 2020 Q3 | 782.1 Million EUR | 1.89% |
| 2020 Q2 | 767.59 Million EUR | 15.14% |
| 2019 Q3 | 98.07 Million EUR | 4.62% |
| 2019 FY | 101.73 Million EUR | 101.9% |
| 2019 Q1 | 89.92 Million EUR | 78.46% |
| 2019 Q2 | 93.74 Million EUR | 4.25% |
| 2019 Q4 | 101.73 Million EUR | 3.73% |
| 2018 Q3 | 47.48 Million EUR | -2.8% |
| 2018 Q2 | 48.85 Million EUR | -5.22% |
| 2018 Q1 | 51.54 Million EUR | -9.14% |
| 2018 Q4 | 50.39 Million EUR | 6.13% |
| 2018 FY | 50.39 Million EUR | -11.17% |
| 2017 FY | 56.72 Million EUR | 17.84% |
| 2017 Q4 | 56.72 Million EUR | 12.57% |
| 2017 Q3 | 50.39 Million EUR | -14.3% |
| 2017 Q2 | 58.79 Million EUR | 12.41% |
| 2017 Q1 | 52.3 Million EUR | 8.66% |
| 2016 Q1 | 38.26 Million EUR | 2.47% |
| 2016 Q2 | 38.05 Million EUR | -0.55% |
| 2016 Q4 | 48.13 Million EUR | 7.87% |
| 2016 Q3 | 44.62 Million EUR | 17.27% |
| 2016 FY | 48.13 Million EUR | 28.91% |
| 2015 Q1 | 40.88 Million EUR | -47.37% |
| 2015 Q2 | 47.07 Million EUR | 15.15% |
| 2015 Q3 | 47.6 Million EUR | 1.12% |
| 2015 Q4 | 37.34 Million EUR | -21.55% |
| 2015 FY | 37.34 Million EUR | -51.92% |
| 2014 Q3 | 86.23 Million EUR | 1.87% |
| 2014 FY | 77.67 Million EUR | -18.67% |
| 2014 Q2 | 84.64 Million EUR | -6.6% |
| 2014 Q4 | 77.67 Million EUR | -9.92% |
| 2014 Q1 | 90.63 Million EUR | -5.11% |
| 2013 Q3 | 103.15 Million EUR | 327.69% |
| 2013 Q4 | 95.51 Million EUR | -7.41% |
| 2013 FY | 95.51 Million EUR | 328.71% |
| 2013 Q1 | 20.6 Million EUR | -7.51% |
| 2013 Q2 | 24.11 Million EUR | 17.05% |
| 2012 Q3 | 26.8 Million EUR | 0.52% |
| 2012 Q4 | 22.27 Million EUR | -16.9% |
| 2012 FY | 22.27 Million EUR | -28.76% |
| 2012 Q1 | 30 Million EUR | -4.06% |
| 2012 Q2 | 26.67 Million EUR | -11.11% |
| 2011 FY | 31.27 Million EUR | 17.43% |
| 2011 Q3 | 39.5 Million EUR | 7.51% |
| 2011 Q4 | 31.27 Million EUR | -20.83% |
| 2011 Q2 | 36.74 Million EUR | -10.18% |
| 2011 Q1 | 40.91 Million EUR | 53.62% |
| 2010 Q1 | 33.19 Million EUR | 3.22% |
| 2010 FY | 26.63 Million EUR | -17.18% |
| 2010 Q3 | 27.37 Million EUR | -39.3% |
| 2010 Q4 | 26.63 Million EUR | -2.72% |
| 2010 Q2 | 45.1 Million EUR | 35.88% |
| 2009 FY | 32.15 Million EUR | -22.15% |
| 2009 Q4 | 32.15 Million EUR | 0.0% |
| 2008 FY | 41.3 Million EUR | 5.44% |
| 2007 FY | 39.17 Million EUR | 40.96% |
| 2006 FY | 27.79 Million EUR | 72.53% |
| 2005 FY | 16.1 Million EUR | -1.88% |
| 2004 FY | 16.41 Million EUR | 5.4% |
| 2003 FY | 15.57 Million EUR | -28.48% |
| 2002 FY | 21.77 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -3609.337% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -20535.122% |
| SQZ Biotechnologies Company | 50.03 Million USD | -3851.442% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -2628.349% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -3250.494% |
| Mesoblast Limited | 188.44 Million USD | -949.254% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -51238.465% |
| Genus plc | 485 Million USD | -307.683% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -33742.037% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -78477.275% |
| Marizyme, Inc. | 26.67 Million USD | -7312.218% |
| ContraFect Corporation | 32.53 Million USD | -5978.085% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -51933.21% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -99695.79% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -51557.362% |
| Intellipharmaceutics International Inc. | 12 Million USD | -16365.154% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -16687.479% |
| MultiCell Technologies, Inc. | 1617.67 USD | -122228906.781% |
| Accustem Sciences Inc. | 1.07 Million USD | -183108.907% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -2454.041% |
| EV Biologics, Inc. | 2.11 Million USD | -93384.514% |
| Q BioMed Inc. | 8.13 Million USD | -24211.777% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -2284.11% |
| Neon Bloom, Inc. | 1.22 Million USD | -161149.471% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -38323.018% |
| Biomind Labs Inc. | 1.49 Million USD | -131839.553% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | -710.111% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -10643.995% |
| Skye Bioscience, Inc. | 14.07 Million USD | -13950.809% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -98264.881% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1391407.072% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -20788.215% |
| IMV Inc. | 37.93 Million USD | -5112.54% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -983045.038% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -34312.175% |
| GB Sciences, Inc. | 5.41 Million USD | -36397.299% |
| Alpha Cognition Inc. | 7.16 Million USD | -27496.99% |
| HST Global, Inc. | 593.59 Thousand USD | -333000.622% |
| CSL Limited | 18.62 Billion USD | 89.382% |
| Halberd Corporation | 728.71 Thousand USD | -271233.94% |
| Enzolytics Inc. | 365.26 Million USD | -441.317% |
| Resverlogix Corp. | 67.39 Million USD | -2833.797% |
| Affymax, Inc. | 8.87 Million USD | -22189.054% |
| SYBLEU INC | 681.41 Thousand USD | -290070.862% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -235644.192% |
| argenx SE | 444.95 Million USD | -344.377% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -2539.164% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -115259.508% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -16511.318% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -53847.435% |
| AVAX Technologies, Inc. | 3.99 Million USD | -49408.969% |
| Zenith Capital Corp. | 27.56 Thousand USD | -7171948.221% |
| Genscript Biotech Corporation | 1.32 Billion USD | -49.129% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -828405.692% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -52848.579% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -290317.631% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -1565.452% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -21767.06% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2954167.917% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -137797.744% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -3833.754% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -72817.542% |
| BioStem Technologies, Inc. | 15.9 Million USD | -12331.961% |
| ONE Bio Corp. | 27.49 Million USD | -7091.139% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -425393.056% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -7207503.886% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -156926.125% |
| Agentix Corp. | 2.51 Million USD | -78657.963% |
| LadRx Corporation | 2.2 Million USD | -89753.979% |
| Cell Source, Inc. | 15.8 Million USD | -12409.001% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4423700.729% |
| Regen BioPharma, Inc. | 5.45 Million USD | -36129.408% |
| Regen BioPharma, Inc. | 5.45 Million USD | -36129.408% |
| NovAccess Global Inc. | 7.86 Million USD | -25053.662% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -7890.22% |
| Itoco Inc. | 1.65 Million USD | -119505.648% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -96278.227% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -32587.419% |
| Kadimastem Ltd | 3.5 Million USD | -56314.751% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -468925.631% |
| CytoDyn Inc. | 127.89 Million USD | -1446.016% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4730304.971% |
| Mobile Lads Corp. | 1.31 Million USD | -150434.183% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -126131.551% |
| Qrons Inc. | 1.48 Million USD | -132716.868% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -17801.406% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -244370.406% |
| Rebus Holdings, Inc. | 5.24 Million USD | -37619.61% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -32304.011% |
| International Stem Cell Corporation | 5.27 Million USD | -37369.433% |
| Bioxytran, Inc. | 3.24 Million USD | -60748.191% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -315852.946% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -42724.528% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -4723.061% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -8780.584% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -97523.91% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -35994.596% |
| Neutra Corp. | 973.52 Thousand USD | -203002.524% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -6714.62% |
| PureTech Health plc | 125.58 Million USD | -1474.466% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -52526.995% |
| IXICO plc | 1.9 Million USD | -103950.429% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -9531.555% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1813.652% |
| CSL Limited | 18.62 Billion USD | 89.382% |
| Cellectis S.A. | 249.36 Million USD | -692.905% |